Literature DB >> 9041310

Revised guidelines for prevention of early-onset group B streptococcal (GBS) infection. American Academy of Pediatrics Committee on Infectious Diseases and Committee on Fetus and Newborn.

.   

Abstract

In 1992, the Committee on Infectious Diseases and Committee on Fetus and Newborn of the American Academy of Pediatrics provided guidelines for prevention of early-onset group B streptococcal (GBS) disease through intrapartum chemoprophylaxis of selected maternal GBS carriers. The guidelines were based on demonstrated efficacy in randomized, controlled clinical trials and selected only women with GBS colonization who had an obstetric risk factor. The guidelines were controversial and their implementation incomplete. Since 1992, additional data have become available, and experience with the guidelines has been gained in numerous medical centers. Recently, consensus guidelines were developed by obstetricians, pediatricians, family practitioners, and public health authorities and published by the Centers for Disease Control and Prevention. These recommendations are supported by the American College of Obstetricians and Gynecologists and the American Academy of Pediatrics. This statement reviews the selection of pregnant women for chemoprophylaxis and provides an algorithm for management of their newborns.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9041310     DOI: 10.1542/peds.99.3.489

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  49 in total

1.  Physicians' prevention practices and incidence of neonatal group B streptococcal disease in 2 Canadian regions.

Authors:  H D Davies; C E Adair; A Schuchat; D E Low; R S Sauve; A McGeer
Journal:  CMAJ       Date:  2001-02-20       Impact factor: 8.262

2.  Prevention of group B streptococcal infection in newborns: recommendation statement from the Canadian Task Force on Preventive Health Care.

Authors: 
Journal:  CMAJ       Date:  2002-04-02       Impact factor: 8.262

3.  Prophylaxis for early onset group B streptococcal sepsis is not so effective in practice.

Authors:  Philip Owen
Journal:  BMJ       Date:  2002-11-02

4.  Mechanisms of macrolide resistance in clinical group B streptococci isolated in France.

Authors:  F Fitoussi; C Loukil; I Gros; O Clermont; P Mariani; S Bonacorsi; I Le Thomas; D Deforche; E Bingen
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

5.  A serotype V clone is predominant among erythromycin-resistant Streptococcus agalactiae isolates in a southwestern region of Germany.

Authors:  Ulrich von Both; Michael Ruess; Urban Mueller; Kirsten Fluegge; Anna Sander; Reinhard Berner
Journal:  J Clin Microbiol       Date:  2003-05       Impact factor: 5.948

6.  Genetic basis of antibiotic resistance in Streptococcus agalactiae strains isolated in a French hospital.

Authors:  Claire Poyart; Laurence Jardy; Gilles Quesne; Patrick Berche; Patrick Trieu-Cuot
Journal:  Antimicrob Agents Chemother       Date:  2003-02       Impact factor: 5.191

7.  Risk Factors for Late-Onset Group B Streptococcal Disease Before and After Implementation of Universal Screening and Intrapartum Antibiotic Prophylaxis.

Authors:  Jillian Pintye; Babette Saltzman; Elizabeth Wolf; Claudia S Crowell
Journal:  J Pediatric Infect Dis Soc       Date:  2015-10-12       Impact factor: 3.164

8.  Evaluation of a new selective enrichment broth for detection of group B streptococci in pregnant women.

Authors:  Judith S Heelan; Judith Struminsky; Patricia Lauro; C James Sung
Journal:  J Clin Microbiol       Date:  2005-02       Impact factor: 5.948

9.  Risk factors for early onset neonatal group B streptococcal sepsis: case-control study.

Authors:  Sam Oddie; Nicholas D Embleton
Journal:  BMJ       Date:  2002-08-10

Review 10.  Laboratory detection of group B Streptococcus for prevention of perinatal disease.

Authors:  F J Picard; M G Bergeron
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-07-16       Impact factor: 3.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.